RSLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 0.01%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

ReShape Lifesciences Insider Trading History Chart

ReShape Lifesciences Share Price & Price History

^$3.16

▼ -0.045 (-1.41%)

As of 08/14/2025 08:50 PM ET

ReShape Lifesciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/25/2023	Thomas Stankovich	CFO	Sell	0	$1,566.00	$0.00	3
10/11/2023	Thomas Stankovich	CFO	Sell	0	$5,394.00	$0.00	3
9/1/2023	Thomas Stankovich	CFO	Sell	0	$5,162.00	$0.00	3
8/24/2023	Thomas Stankovich	CFO	Sell	0	$8,236.00	$0.00	4
8/4/2023	Thomas Stankovich	CFO	Sell	0	$8,294.00	$0.00	4
7/6/2023	Thomas Stankovich	CFO	Sell	0	$8,526.00	$0.00	4
6/30/2023	Thomas Stankovich	CFO	Buy	3	$8,816.00	$26,448.00	4
5/31/2023	Thomas Stankovich	CFO	Sell	0	$13,978.00	$0.00
4/30/2023	Thomas Stankovich	CFO	Sell	0	$13,688.00	$0.00	1
3/31/2023	Thomas Stankovich	CFO	Sell	0	$15,080.00	$0.00	1
2/28/2023	Thomas Stankovich	CFO	Sell	0	$24,650.00	$0.00	1
2/2/2023	Thomas Stankovich	CFO	Sell	0	$77,082.00	$0.00	1
1/24/2023	Thomas Stankovich	CFO	Sell	0	$43,442.00	$0.00	1

SEC Filings (Institutional Ownership Changes) for ReShape Lifesciences (NASDAQ:RSLS)

22.06% of ReShape Lifesciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

ReShape Lifesciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	Armistice Capital LLC	188,000	$64K	0.0%	N/A	5.449%
5/11/2022	GSA Capital Partners LLP	36,490	$43K	0.0%	N/A	0.196%
11/15/2021	Sassicaia Capital Advisers LLC	10,000	$29K	0.1%	N/A	0.063%
8/16/2021	State Street Corp	109,999	$0.55M	0.0%	N/A	3.293%

Data available starting January 2016

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Today's Range

Now: $3.16

$2.80

$4.65

50 Day Range

MA: $7.36

$3.16

$15.68

52 Week Range

Now: $3.16

$1.87

$303.25

Volume

13,689,666 shs

Average Volume

3,322,808 shs

Market Capitalization

$8.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16